Expertise in
6
conditions

Dr. Jeffrey T. Guptill

Neurology
Office
Durham, NC 
Expertise in
6
conditions
Office
Durham, NC 

Overview

Jeffrey Guptill is a Neurologist practicing medicine in Durham, North Carolina.

Dr. Guptill is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Myasthenia Gravis, Lambert-Eaton Syndrome, Chronic Polyradiculoneuritis, Chronic Inflammatory Demyelinating Polyneuropathy, and Thymectomy.

He is actively involved in clinical research, co-authoring 91 peer reviewed articles and participating in 6 clinical trials.

Specialties

Neurology

Licenses

Psychiatry & Neurology in NC

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Office
Durham, NC 27710

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Double-Blind, Placebo-controlled, Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and CSF Capture Study of the Safety, Pharmacokinetics and Pharmacodynamics of (2R,6R)-Hydroxynorketamine in Healthy Volunteers
A Double-Blind, Placebo-controlled, Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) and CSF Capture Study of the Safety, Pharmacokinetics and Pharmacodynamics of (2R,6R)-Hydroxynorketamine in Healthy Volunteers
Enrollment Status: Completed
Publish Date: June 06, 2024
Intervention Type: Drug
Study Drug: (2R,6R)-Hydroxynorketamine Hydrochloride
Study Phase: Phase 1
A Phase 1a, Double-Blind, Randomized, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of MW151 Administered Orally to Healthy Volunteers
A Phase 1a, Double-Blind, Randomized, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of MW151 Administered Orally to Healthy Volunteers
Enrollment Status: Completed
Publish Date: December 30, 2022
Intervention Type: Drug
Study Drug: MW151
Study Phase: Phase 1
A Phase 1, Randomized, Controlled, Observer-blind Study to Assess the Reactogenicity, Safety, and Immunogenicity of a Live Attenuated Universal Influenza Vaccine (cH8/1N1 LAIV) Administered as a Single Priming Dose Followed Three Months Later by a Single Booster Dose of an Inactivated Universal Influenza Vaccine (cH5/1N1 IIV) (Adjuvanted With AS03A or Unadjuvanted) in 18 Through 39 Year-old Healthy Subjects, Contrasted With a Two Dose Schedule of an Inactivated Universal Influenza Vaccine (cH8/1N1 IIV + AS03A Followed Three Months Later by cH5/1N1 IIV + AS03A)
A Phase 1, Randomized, Controlled, Observer-blind Study to Assess the Reactogenicity, Safety, and Immunogenicity of a Live Attenuated Universal Influenza Vaccine (cH8/1N1 LAIV) Administered as a Single Priming Dose Followed Three Months Later by a Single Booster Dose of an Inactivated Universal Influenza Vaccine (cH5/1N1 IIV) (Adjuvanted With AS03A or Unadjuvanted) in 18 Through 39 Year-old Healthy Subjects, Contrasted With a Two Dose Schedule of an Inactivated Universal Influenza Vaccine (cH8/1N1 IIV + AS03A Followed Three Months Later by cH5/1N1 IIV + AS03A)
Enrollment Status: Completed
Publish Date: February 21, 2021
Intervention Type: Biological
Study Phase: Phase 1
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of lGIV-C as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of lGIV-C as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
Enrollment Status: Completed
Publish Date: March 30, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients With Skin Diseases
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients With Skin Diseases
Enrollment Status: Completed
Publish Date: May 03, 2019
Intervention Type: Drug
Study Phase: Phase 1
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects With Generalized Myasthenia Gravis
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects With Generalized Myasthenia Gravis
Enrollment Status: Completed
Publish Date: March 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

91 Total Publications

FcRn inhibitors: A new era in neurotherapeutics.
FcRn inhibitors: A new era in neurotherapeutics.
Journal: Handbook of clinical neurology
Published: January 12, 2026
Similar Doctors
Expertise in
72
conditions
Expertise in
72
conditions
Referral required
Before you request

Duke Muscular Dystrophy Association (MDA) Clinic - Clinic 1L

40 Duke Medicine Cir, 
Durham, NC 
 (2.2 miles away)
919-681-5176
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Vern Juel is a Neurologist practicing medicine in Durham, North Carolina. Dr. Juel is highly rated in 72 conditions, according to our data. His clinical expertise encompasses Myasthenia Gravis, Lambert-Eaton Syndrome, Inclusion Body Myositis, Meige Syndrome, and Thymectomy. Dr. Juel is board certified in American Board Of Psychiatry/Neurology, Clinical Neurophysiology , American Board Of Psychiatry/Neurology, Neuromuscular Medicine, and American Board Of Psychiatry/Neurology, Neurology . Dr. Juel is currently accepting new patients.

Expertise in
8
conditions
Expertise in
8
conditions
Referral may be required

Office

177 Research Dr # B, 
Durham, NC 
 (0.1 miles away)
919-684-5018
Languages Spoken:
English
See accepted insurances

Darell Bigner is a Neurologist practicing medicine in Durham, North Carolina. Dr. Bigner is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Glioma, Gliomatosis Cerebri, and Glioblastoma.

Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (19.5 miles away)
713-792-6161
Languages Spoken:
English

Marta Penas-Prado is a Neurologist practicing medicine in Cary, North Carolina. Dr. Penas-Prado is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Astrocytoma, Glioblastoma, Brain Tumor, and Glioma.

Frequently Asked Questions about Dr. Jeffrey T. Guptill

How do I make an appointment with Dr. Jeffrey T. Guptill?

You can book an appointment with Dr. Jeffrey T. Guptill by calling their office at 919-684-8111. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jeffrey T. Guptill a top-rated expert for Myasthenia Gravis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jeffrey T. Guptill is classified as an Elite expert for Myasthenia Gravis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jeffrey T. Guptill specialize in?

While Dr. Jeffrey T. Guptill is a Neurology, they have specific expertise in Myasthenia Gravis, Lambert-Eaton Syndrome, and Chronic Polyradiculoneuritis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Jeffrey T. Guptill participate in research or clinical trials?

Yes. Dr. Jeffrey T. Guptill has published 91 articles and abstracts on conditions like Myasthenia Gravis. You can view a list of Dr. Jeffrey T. Guptill's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Guptill's expertise for a condition
ConditionClose
View All 43 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile